SG Americas Securities LLC Acquires 76,233 Shares of Becton, Dickinson and Company $BDX

SG Americas Securities LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,799 shares of the medical instruments supplier’s stock after buying an additional 76,233 shares during the quarter. SG Americas Securities LLC owned about 0.08% of Becton, Dickinson and Company worth $44,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. HB Wealth Management LLC grew its stake in Becton, Dickinson and Company by 42.1% during the third quarter. HB Wealth Management LLC now owns 32,650 shares of the medical instruments supplier’s stock valued at $6,111,000 after acquiring an additional 9,678 shares in the last quarter. Texas Bank & Trust Co grew its position in shares of Becton, Dickinson and Company by 8.6% during the third quarter. Texas Bank & Trust Co now owns 2,392 shares of the medical instruments supplier’s stock valued at $448,000 after purchasing an additional 190 shares in the last quarter. CX Institutional increased its stake in Becton, Dickinson and Company by 3.6% in the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 60 shares during the last quarter. Park Avenue Securities LLC increased its position in Becton, Dickinson and Company by 22.1% in the third quarter. Park Avenue Securities LLC now owns 5,363 shares of the medical instruments supplier’s stock worth $1,004,000 after purchasing an additional 971 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Becton, Dickinson and Company by 30.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 1,090 shares of the medical instruments supplier’s stock valued at $204,000 after buying an additional 254 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 1,052 shares of company stock worth $201,235. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Jefferies Financial Group lifted their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Bank of America raised their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $207.64.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $202.74 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market capitalization of $57.76 billion, a PE ratio of 34.78, a P/E/G ratio of 2.27 and a beta of 0.23. The company has a 50 day moving average price of $192.11 and a 200-day moving average price of $187.77. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.